中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2014年
4期
348-351
,共4页
张颖%王艳强%肖志清%刘会芝%刘军领%薛晓英
張穎%王豔彊%肖誌清%劉會芝%劉軍領%薛曉英
장영%왕염강%초지청%류회지%류군령%설효영
体层摄影术,X线计算机,四维%计划靶体积%剂量学%食管肿瘤/放射疗法
體層攝影術,X線計算機,四維%計劃靶體積%劑量學%食管腫瘤/放射療法
체층섭영술,X선계산궤,사유%계화파체적%제량학%식관종류/방사요법
Tomography,X-ray computed,four-dimensional%Planning target volume%Dosimetry%Esophageal neoplasms/radiotherapy
目的 比较胸中下段食管癌3D、4D放疗计划的靶区大小、靶区位移及相关剂量学差异,评估4D计划的临床价值.方法 2012年内19例胸中下段食管癌患者分别在同次CT模拟定位时序贯行3D、4D扫描,模拟勾画二者靶区及OAR.设计3D计划和4D计划,比较3D计划与4D计划靶体积、中心点位移及OAR剂量学差异.在各项参数相同下将3D计划平移至4DCT形成3DC计划,并比较3DC计划与3D计划靶区剂量学差异.采用配对t检验或Wilcoxon符号秩检验两套计划差异.结果 全组4DCT的PTV大于3DCT (195.19 cm3∶175.67 cm3,P=0.001).10例胸中段食管癌中心点位移仅左右方向不同(位移为0.25 cm,P=0.014).9例胸下段食管癌中心点位移3个方向差异无统计学意义(P =0.722、0.307、0.208).19例胸中下段食管癌3DC计划中V100、V45、V90均低于3D计戈 (88.62%∶ 95.69%,P=0.000; 95.17%∶ 99.79%,P=0.001; 97.19%∶ 99.99%,P=0.001).全组4D计划两肺V5、V20及心脏Dmean均高于3D计划(39.49%∶37.44%,P=0.016;19.93%∶18.87%,P=0.018及2607.74 cGy∶ 2389.16 cGy,P=0.004),但均未超出剂量限制范围.结论 4DCT定位技术能准确确定胸中下段食管癌靶区个体化外扩边界,4D计划因靶区增大虽使肺受量增加但在剂量限制范围内,4D计划使心脏受量增加应引起注意.
目的 比較胸中下段食管癌3D、4D放療計劃的靶區大小、靶區位移及相關劑量學差異,評估4D計劃的臨床價值.方法 2012年內19例胸中下段食管癌患者分彆在同次CT模擬定位時序貫行3D、4D掃描,模擬勾畫二者靶區及OAR.設計3D計劃和4D計劃,比較3D計劃與4D計劃靶體積、中心點位移及OAR劑量學差異.在各項參數相同下將3D計劃平移至4DCT形成3DC計劃,併比較3DC計劃與3D計劃靶區劑量學差異.採用配對t檢驗或Wilcoxon符號秩檢驗兩套計劃差異.結果 全組4DCT的PTV大于3DCT (195.19 cm3∶175.67 cm3,P=0.001).10例胸中段食管癌中心點位移僅左右方嚮不同(位移為0.25 cm,P=0.014).9例胸下段食管癌中心點位移3箇方嚮差異無統計學意義(P =0.722、0.307、0.208).19例胸中下段食管癌3DC計劃中V100、V45、V90均低于3D計戈 (88.62%∶ 95.69%,P=0.000; 95.17%∶ 99.79%,P=0.001; 97.19%∶ 99.99%,P=0.001).全組4D計劃兩肺V5、V20及心髒Dmean均高于3D計劃(39.49%∶37.44%,P=0.016;19.93%∶18.87%,P=0.018及2607.74 cGy∶ 2389.16 cGy,P=0.004),但均未超齣劑量限製範圍.結論 4DCT定位技術能準確確定胸中下段食管癌靶區箇體化外擴邊界,4D計劃因靶區增大雖使肺受量增加但在劑量限製範圍內,4D計劃使心髒受量增加應引起註意.
목적 비교흉중하단식관암3D、4D방료계화적파구대소、파구위이급상관제량학차이,평고4D계화적림상개치.방법 2012년내19례흉중하단식관암환자분별재동차CT모의정위시서관행3D、4D소묘,모의구화이자파구급OAR.설계3D계화화4D계화,비교3D계화여4D계화파체적、중심점위이급OAR제량학차이.재각항삼수상동하장3D계화평이지4DCT형성3DC계화,병비교3DC계화여3D계화파구제량학차이.채용배대t검험혹Wilcoxon부호질검험량투계화차이.결과 전조4DCT적PTV대우3DCT (195.19 cm3∶175.67 cm3,P=0.001).10례흉중단식관암중심점위이부좌우방향불동(위이위0.25 cm,P=0.014).9례흉하단식관암중심점위이3개방향차이무통계학의의(P =0.722、0.307、0.208).19례흉중하단식관암3DC계화중V100、V45、V90균저우3D계과 (88.62%∶ 95.69%,P=0.000; 95.17%∶ 99.79%,P=0.001; 97.19%∶ 99.99%,P=0.001).전조4D계화량폐V5、V20급심장Dmean균고우3D계화(39.49%∶37.44%,P=0.016;19.93%∶18.87%,P=0.018급2607.74 cGy∶ 2389.16 cGy,P=0.004),단균미초출제량한제범위.결론 4DCT정위기술능준학학정흉중하단식관암파구개체화외확변계,4D계화인파구증대수사폐수량증가단재제량한제범위내,4D계화사심장수량증가응인기주의.
Objective To study the PTV by ng 4DCT and compare target,target displacement and dose distribution of 3D and 4D planning for thoracic middle or lower esophageal cancer,evaluate the clinical value of 4DCT in esophageal cancer radiotherapy.Methods From Jan to Dec 2012patients with primary esophageal cancer underwent 3DCT simulation scans first,then followed by 4DCT simulation scan.PTV and OARs were sketched in the ordinary 3DCT and 4DCT respectively.And designing two sets of radiotherapy plan for each patient:3D and 4D plan.We compare PTV,PTV displacement and OARs dosimetry's differences in the 3D plan and 4D plan.Using the paired t-test or Wilcoxon sign-rank test to compare the difference between the two sets of plans.Results The volume of PTV4D was larger than the PTV3D (195.19 cm3 vs.175.67 cm3,P =0.001) in all patients.The center displacement had only significantly difference (displacement was 0.25 cm,P =0.014) in left-right direction for 10 patients of thoracic middle esophageal cancer.The center displacement had no significantly different in the three direction for 9 patients of thoracic under esophageal cancer (P=0.722,0.307,0.208).The dose target area of V100,V95 and V90 in Plan3DC were significantly than those in Plan-3D for 19 patients of thoracic middle-lower esophageal cancer (88.62% vs.95.69%,P=0.000;95.17% vs.99.79%,P=0.001;97.19% vs.99.99%,P=0.001).In 4D plan the lung V5,V20 and Dmean of heart were higher than that in 3D plan for all patients (39.49%vs.37.44%,P=0.016;19.93% vs.18.87%,P=0.018 and 2607.74 cGy vs.2389.16 cGy,P=0.004).Conclusions 4DCT positioning technology can accuracy determine individualized expanding boundary by target area of radiotherapy for thoracic middle or lower esophageal cancer.The enlarging target volume increase the dose of radiotherapy for lung,and in the dose range in the 4D plan,but the increased dose of heart should be noted.